Complete Kinase Inhibitor Characterization: Integrating Activity, Binding, and Cellular Target Engagement
A comprehensive screening cascade requires multiple orthogonal data types: direct catalytic activity, biophysical binding affinity and kinetics, and cellular target engagement. Reaction Biology offers assay platforms that can resolve all three.
Why Kinase Selectivity Demands Multiple Assay Formats
The human kinome comprises more than 500 kinases sharing a conserved ATP-binding pocket and high structural homology. This conservation is the central obstacle in kinase drug discovery: a compound potent against its primary target frequently engages structurally related off-targets, and inadequate early characterization allows those liabilities to surface downstream as unexplained toxicity or loss of efficacy.
Each assay format answers a distinct question:
- Activity assays quantify functional inhibition of catalytic turnover, which is the central driver in modulating cell functions
- Binding assays detect target engagement, even including engagement that does not alter catalytic output, or engagement with enzymes at inactive state
- Cellular assays confirm engagement and function in an intact cellular environment
A characterization strategy limited to one format inherits that format’s blind spots. Integrating all three, sequenced appropriately, resolves compound behavior before committing to lead optimization.
Reaction Biology provides all three data types across a single, integrated platform.
Stage 1: Direct Activity Measurement for Functional Inhibition
The majority of kinase inhibitor programs target kinase enzymatic activities, for which the therapeutic mechanism is inhibition of catalytic phosphorylation. Direct activity measurement quantifies this mechanism without reliance on a surrogate readout.
HotSpot™ is a radiometric filter-binding assay that measures transfer of ³³P-labeled phosphate from ATP to the kinase substrate. The signal directly measures phosphate transfer from ATP to substrate, providing a proximal readout of catalytic activity and enabling measurement of function inhibition.
Radiometric detection delivers capabilities that indirect and label-dependent formats cannot:
- Largest kinase library in the industry: 850+ kinases, including 700+ wild-type kinases plus the deepest commercial collection of clinically relevant mutants and oncogenic fusions
- Physiological ATP: screening at 1 µM to 1 mM ATP. ATP-competitive potency is ATP-concentration dependent; measurement at physiological ATP concentrations often improve prediction of cellular behavior (assays that omit ATP cannot provide this)
- Native, unmodified substrates: proteins and peptides used without labeling or chemical modification
- No-counter assays required: all signals are the results of direct drug-kinase interactions, not interferences from coupling enzymes or antibodies
- Mode-of-action studies: ATP-competitive, substrate-competitive, allosteric, and irreversible mechanisms resolved directly
³³PanQinase™ provides an independent radiometric panel via a scintillant-coated ScintiPlate assay at the Freiburg, Germany facility. As a mechanistically separate assay from HotSpot, it enables orthogonal cross-site screening to identify false positives.
Explore Kinase Panel Screening →
Stage 2: Biophysical Binding for Affinity, Kinetics, and Allosteric Detection
Activity assays may not identify compounds whose primary effect is not reflected in the chosen catalytic readout, such as allosteric binder targeting the regulatory domain and ligands only bind to the inactive form.
A critical and frequently overlooked determinant of allosteric detection is the protein construct, not the assay format. When only a kinase catalytic domain is expressed, because the full-length protein is difficult to produce or has poor activity, allosteric sites elsewhere on the protein are absent from the assay entirely.
Both activity and binding assays may detect allosteric engagement when the relevant regulatory domains are present in the protein construct.
Binding is also conformation-dependent. Substrate, ATP, and drug binding all reshape kinase folding through induced fit, a general property of enzyme targets. A binding assay conducted without ATP and substrate may capture a conformation distinct from the catalytically active state, which is an important reason target occupancy does not always correlate with functional inhibition.
Surface Plasmon Resonance (SPR), performed on Biacore 8K and 8K+ instruments in Malvern, PA, measures direct, label-free binding independent of catalytic activity:
- Affinity, kinetics, and residence time: association and dissociation rate constants, equilibrium Kd, and residence time, a kinetic parameter that in some target classes has been associated with improved pharmacodynamic activity and in vivo efficacy
- No enzyme or substrate required: direct binding measurement suits pseudokinases, non-catalytic proteins, and targets with unknown substrates
- Fragment screening: low-affinity fragments (100 to 300 Da) require high test concentrations, better tolerated by SPR than by many biochemical assays
- False-positive resolution: SPR can help identify assay artifacts and distinguish specific from nonspecific interactions as part of an orthogonal screening strategy.
Complementary biophysical methods extend binding characterization: Isothermal Titration Calorimetry (ITC) provides label-free thermodynamic analysis in solution without immobilization, and Microscale Thermophoresis (MST) provides solution-phase affinity measurement. Together they deliver orthogonal confirmation of binding affinity and thermodynamics.
Stage 3: Cellular Target Engagement for Physiological Confirmation
A compound that binds in solution and inhibits an isolated enzyme must still function inside a living cell, where ATP, competing proteins, and membrane permeability apply. Cellular assays confirm that biochemical performance translates to the cellular environment.
NanoBRET™ Target Engagement, measures intracellular compound binding to a kinase target and quantifies intracellular residence time. The readout reflects physiological ion and ATP concentration, pH, and captures cell permeability, which biochemical and biophysical assays cannot. For targeted protein degraders and molecular glues, whose mechanism depends on productive intracellular engagement, cellular target engagement is a critical mechanistic readout. NanoBRET panels now extend to kinase mutants alongside wild-type targets.
Cellular Phosphorylation Assay confirms that biochemical inhibition translates to reduced pathway signaling in cells, linking target engagement to a functional downstream consequence.
Cellular residence time from NanoBRET combined with cell-free kinetics from SPR provides binding kinetics across both biochemical and cellular contexts.
Explore NanoBRET Assay Services →
Explore Cellular Phosphorylation Assay Services →
Integrated Kinase Characterization From a Single Provider
Selectivity and mechanism are most reliably established using complementary readouts, rather than a single assay format. Rigorous kinase inhibitor characterization requires orthogonal data, not binding or activity in isolation.
Direct activity measurement quantifies functional inhibition of catalytic turnover at physiological ATP. Biophysical binding resolves affinity, kinetics, and engagement that activity assays cannot detect, including allosteric and non-inhibitory binders. Cellular assays confirm that biochemical performance translates to target engagement inside an intact cell.
Reaction Biology delivers the complete cascade: the industry’s largest kinase activity panel, a full biophysical binding suite, and cellular target engagement, supported by scientists who match each assay format to the scientific question at every stage of your program.
